AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.010

0.000

Volume:4.96M

Turnover:50.25K

Market Cap:43.38M

PE:-0.53

High:0.011

Open:0.010

Low:0.010

Close:0.010

52wk High:0.040

52wk Low:0.009

Shares:4.34B

Float Shares:3.34B

Volume Ratio:0.20

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.019

EPS(LYR):-0.018

ROE:-92.10%

ROA:-28.33%

PB:0.84

PE(LYR):-0.54

Loading ...

Overview Company News Filings

Radiopharm Says In-Human Trial Results Show 'Meaningful' Tumor Uptake, Favorable Safety Profile for Radiotherapeutic Candidate

MT Newswires Live

Radiopharm Theranostics Ltd-Rad Initial Findings From Phase 1 177Lu-Rad202 Trial

THOMSON REUTERS

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2B Imaging Trial of Rad 101 for Diagnosis of Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Completes Dosing of Final Patient in Phase 2B Imaging Trial in Recurrent Brain Metastases from Solid Tumors

MT Newswires Live

BRIEF-Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-Rad202 Phase 1 Dose Escalating Clinical Trial

THOMSON REUTERS

Radiopharm Theranostics Ltd: on Track to Complete Phase 1 Dose Escalation by End of 2026

THOMSON REUTERS

Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%

MT Newswires Live

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for Rad101 in the U.S.

THOMSON REUTERS

BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101

Radiopharm Theranostics Ltd - Rad and Siemens Sign Clinical Supply Agreement for Rad101

THOMSON REUTERS

Radiopharm Theranostics director Noel Donnelly files initial beneficial ownership statement

Radiopharm Theranostics files Form 3 for director Denise Hester Larkin

Radiopharm Theranostics Ltd: Doses First Patient in Phase 1 Clinical Study of Rad 402 in Advanced Prostate Cancer

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient In Phase One Advanced Prostate Cancer Drug Candidate Trial

MT Newswires Live

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

Radiopharm Theranostics Achieves Primary Endpoint in 90% of Patients at Second Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Meets Primary Endpoint in 90% of Patients in Brain Imaging Trial

MT Newswires Live

Radiopharm Theranostics to present at NWR Virtual Healthcare Conference

Radiopharm Theranostics Ltd. Director Bruce Michael Goodwin Files Initial Beneficial Ownership Statement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/RAD.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.01,"timestamp":1787292720000,"preClose":0.01,"halted":0,"volume":4959375,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.019034,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-21 16:12:00 AEST","open":0.01,"high":0.011,"low":0.01,"amount":50250,"amplitude":0.1,"askPrice":0.011,"askSize":1836974,"bidPrice":0.01,"bidSize":14762,"shortable":3,"etf":0,"ttmEps":-0.019034,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.19748640911225376,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.01,"auctionPrice":0.01,"auctionVolume":178500,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292595380}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-28.33%","roe":"-92.10%","lyrEps":-0.018424,"volumeRatio":0.19748640911225376,"shares":4337549000,"dividePrice":0,"high":0.011,"amplitude":0.1,"preClose":0.01,"low":0.01,"week52Low":0.009,"pbRate":"0.84","psRate":"2.66","week52High":0.04,"institutionHeld":0,"latestPrice":0.01,"committee":-0.984056,"eps":-0.019034,"divideRate":0,"volume":4959375,"delay":0,"ttmEps":-0.019034,"open":0.01,"prevYearClose":0.025,"prevWeekClose":0.01,"prevMonthClose":0.014,"prevQuarterClose":0.019,"fiveDayClose":0.011,"twentyDayClose":0.019,"sixtyDayClose":0.021,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628157977","title":"Radiopharm Says In-Human Trial Results Show 'Meaningful' Tumor Uptake, Favorable Safety Profile for Radiotherapeutic Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2628157977","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628157977?lang=en_us&edition=fundamental","pubTime":"2026-04-20 12:05","pubTimestamp":1776657931,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  said the first in-human findings from the ongoing Phase 0/1 HEAT trial evaluating its radiotherapeutic candidate, lutetium-177-RAD202, showed \"meaningful\" tumor uptake and a favorable safety profile at the lowest dose level of 30 millicurie , according to a Monday Australian bourse filing.Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation, while no dose-limiting toxicities or treatment discontinuations due to adverse events were observed, per the filing.The radiotherapeutic candidate was generally well tolerated in the first three treated patients, with predominantly grade one to two treatment-emergent adverse events, the filing added.Radiopharm Theranostics' shares rose past 2% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628799033","title":"Radiopharm Theranostics Ltd-Rad Initial Findings From Phase 1 177Lu-Rad202 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2628799033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628799033?lang=en_us&edition=fundamental","pubTime":"2026-04-20 06:54","pubTimestamp":1776639291,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nTUEBXGNC7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627942502","title":"Radiopharm Theranostics Completes Enrollment in U.S. Phase 2B Imaging Trial of Rad 101 for Diagnosis of Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2627942502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627942502?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:00","pubTimestamp":1776337201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA5YJYBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257450","title":"Radiopharm Theranostics Completes Dosing of Final Patient in Phase 2B Imaging Trial in Recurrent Brain Metastases from Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257450","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257450?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:17","pubTimestamp":1776305846,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  completed the dosing of the final patient in the US phase 2b imaging trial evaluating the diagnostic performance of fluorine-18-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins, according to a Thursday Australian bourse filing.The primary objective of the study is concordance between fluorine-18-RAD101 positive lesions and those seen in conventional imaging, magnetic resonance imaging with gadolinium, in participants with suspected recurrent brain metastases.RAD 101 is a novel imaging small molecule that targets fatty acid synthase , a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946766","title":"BRIEF-Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625946766?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:14","pubTimestamp":1775650496,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical TrialApril 8 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:RADIOPHARM THERANOSTICS ADVANCES TO COHO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625948007","title":"Radiopharm Theranostics Advances to Cohort 3 in 177Lu-Rad202 Phase 1 Dose Escalating Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2625948007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625948007?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:01","pubTimestamp":1775646063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R18I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625438599","title":"Radiopharm Theranostics Ltd: on Track to Complete Phase 1 Dose Escalation by End of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625438599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625438599?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:01","pubTimestamp":1775646063,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R18I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625990372","title":"Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625990372","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625990372?lang=en_us&edition=fundamental","pubTime":"2026-04-08 14:19","pubTimestamp":1775629155,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie  from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 -positive advanced solid tumors, according to a Wednesday Australian bourse filing.The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.Its shares rose 5% in recent trading on Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625932378","title":"Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for Rad101 in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625932378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625932378?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:00","pubTimestamp":1775559603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA64DWPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625986839","title":"BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2625986839","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625986839?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:28","pubTimestamp":1775528920,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101April 7  - Radiopharm Theranostics Ltd RAD.AX:RAD AND SIEMENS SIGN CLINICAL SUPPLY AGREEMENT FOR RAD101SIEMENS HEALTHINEERS WILL RADIOLABEL, DISTRIBUTE RAD101 WITH FLUORINE-18 Further company coverage: RAD.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625607639","title":"Radiopharm Theranostics Ltd -  Rad and Siemens Sign Clinical Supply Agreement for Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2625607639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625607639?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:31","pubTimestamp":1775514700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624261595","title":"Radiopharm Theranostics director Noel Donnelly files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624261595","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624261595?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:46","pubTimestamp":1775094416,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Noel Donnelly reported options to buy 8 million ordinary shares exercisable at AUD 0.06, with expirations through Sept. 30, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1w6z3s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551776","title":"Radiopharm Theranostics files Form 3 for director Denise Hester Larkin","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551776","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551776?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:31","pubTimestamp":1774999904,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Denise Hester Larkin filed an initial Form 3 showing 644,247 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLc5HNrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829814","title":"Radiopharm Theranostics Ltd: Doses First Patient in Phase 1 Clinical Study of Rad 402 in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829814?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:10","pubTimestamp":1774613453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622736890","title":"Radiopharm Theranostics Doses First Patient In Phase One Advanced Prostate Cancer Drug Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622736890","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622736890?lang=en_us&edition=fundamental","pubTime":"2026-03-27 08:22","pubTimestamp":1774570973,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  dosed the patient in its first-in-human phase one clinical trial of its RAD 402 drug candidate in advanced prostate cancer, according to a Friday Australian bourse filing.The trial is designed to study the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with advanced prostate cancer, while the dose escalation phase one study is designed to determine the maximum tolerated dose and/or recommended phase two dose for expansion.RAD 402 is a monoclonal antibody targeting KLK3 radiolabelled with the radionuclide terbium 161.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z4B17.USD","AEIS","BK7067","LU0757428866.USD","BK4157","LU1815336091.USD","IE00B66KJ199.SGD","IE0031619046.USD","RAD.AU","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622188031","title":"$10,000 invested in this ASX healthcare share a year ago is now worth $36,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2622188031","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622188031?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:53","pubTimestamp":1774497205,"startTime":"0","endTime":"0","summary":"ASXhealthcare share Starpharma Holdings Ltd  has rocketed 365% over the past 12 months.Had you put $10,000 into this ASXsmall-capshare in March 2025, your holdings would be worth $36,500 today.These nanoscale molecules make medicines more effective in the body.Starpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.This ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.What's behind the dramatic 365% share price rise?In September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships.Starpharma signed a research and option agreement with Radiopharm Theranostics Ltd that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.Is it too late to buy this rising ASX healthcare share?ASX biotech shares are notoriously risky and unsuitable for investors with a low risk toleranc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK7501","RAD.AU","VHT","BK4585","IXJ","BK7067","BK4588","SPL.AU","BK7508","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621066404","title":"Radiopharm Theranostics Achieves Primary Endpoint in 90% of Patients at Second Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621066404?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:01","pubTimestamp":1774350066,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C02O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621344900","title":"Radiopharm Theranostics Meets Primary Endpoint in 90% of Patients in Brain Imaging Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621344900","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621344900?lang=en_us&edition=fundamental","pubTime":"2026-03-24 10:42","pubTimestamp":1774320161,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics'  second interim analysis from its phase 2b clinical imaging trial of RAD 101 in brain metastases showed that 90% of patients achieved concordance between positron emission tomography imaging and magnetic resonance imaging  for detecting brain metastases, achieving the primary endpoint, according to a Tuesday filing with the Australian bourse.RAD 101 is the company's small-molecule imaging agent targeting fatty acid synthase and radiolabeled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from various solid tumors, the filing said.The results indicated \"significant\" and selective tumor uptake in brain metastases, with images confirming metabolic activity compared with equivocal MRI scans.Additionally, the first five patients with evaluable six-month follow-up and biopsy data in the trial indicated a positive trend for sensitivity and specificity, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620249687","title":"Radiopharm Theranostics to present at NWR Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620249687","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620249687?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:23","pubTimestamp":1773915795,"startTime":"0","endTime":"0","summary":"Radiopharm is scheduled to present at the NWR Virtual Healthcare Conference at 8:30am AEDT on 25 March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbVRF9m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620256688","title":"Radiopharm Theranostics Ltd. Director Bruce Michael Goodwin Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256688","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620256688?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:56","pubTimestamp":1773838603,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics reported an initial statement of beneficial ownership naming Bruce Michael Goodwin as a director. The filing stated that Bruce Michael Goodwin beneficially owned no securities of the company as of 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8YD9hj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":66,"code":"91000000","status":"200"}]}}